@article {DiMariae230371, author = {Christina DiMaria and Wael Hanna and Julie Murone and James Reichart}, title = {Direct oral anticoagulant and AKI: apixaban-induced acute interstitial nephritis}, volume = {12}, number = {6}, elocation-id = {e230371}, year = {2019}, doi = {10.1136/bcr-2019-230371}, publisher = {BMJ Specialist Journals}, abstract = {Direct oral anticoagulants (DOACs){\textemdash}dabigatran, rivaroxaban, apixaban and edoxaban{\textemdash}are changing the landscape of clinical practice for patients requiring short and long-term anticoagulation. We report a patient with no history of kidney disease developing acute interstitial nephritis (AIN) after starting a DOAC, apixaban. To date, this is the first biopsy proven case of apixaban-induced AIN.}, URL = {https://casereports.bmj.com/content/12/6/e230371}, eprint = {https://casereports.bmj.com/content/12/6/e230371.full.pdf}, journal = {BMJ Case Reports CP} }